1,6-Diazaspiro[2.5]octane | 36706-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1,6-Diazaspiro[2.5]octane
• CAS: 36706-65-7
• 化学式: C₆H₁₂N₂
• 分子量: 112.17
• InChiKey: KUYMEVLKUJVHKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  34
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ ROR-GAMMA
  申请人：BIOGEN IDEC INC

  公开号：WO2014028669A1

  公开（公告）日：2014-02-20

  The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases.

  本发明涉及芳基砜和相关化合物，它们是ROR-gamma受体的调节剂。该发明还提供包含这些调节剂的药物组合物，以及使用它们调节ROR-gamma受体的方法。还提供了使用芳基砜和相关化合物作为ROR-gamma调节剂治疗ROR-gamma介导疾病的方法。
• METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150099875A1

  公开（公告）日：2015-04-09

  The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.

  本发明涉及通过顺序亲核芳香取代法合成2,4-二取代嘧啶的新颖区域选择性合成。
• HETEROCYCLIC SPIRO COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1683797A1

  公开（公告）日：2006-07-26

  The compound represented by formula (I) (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing at least one carbon atom and one nitrogen atom and the ringA and ringB share one spiro carbon atom.), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.

  公式（I）所代表的化合物（其中D和G是可能具有取代基的环族，或者是可能具有取代基的烷基，W和Y是具有1-4个原子编号的主链的键或间隔物，环A和环B是可能具有取代基的杂环，含有至少一个碳原子和一个氮原子，环A和环B共享一个螺环碳原子），其盐，N-氧化物或溶剂合物，或其前药。由于公式（I）所代表的化合物，其盐，N-氧化物或溶剂合物，或其前药对MBR具有亲和力，因此它们对于预防和/或治疗由压力引起的疾病是有用的。
• Heterocyclic Spiro Compound
  申请人：Ohmoto Kazuyuki

  公开号：US20070275990A1

  公开（公告）日：2007-11-29

  The compound represented by formula (I) (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing at least one carbon atom and one nitrogen atom and the ringA and ringB share one spiro carbon atom), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof. Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.

  化合物的化学式为（I）（其中D和G是环状基团，可能有取代基或烷基，也可能有取代基；W和Y是键或间隔物，其主链具有1-4个原子数；环A和环B是杂环环，可能有取代基，含有至少一个碳原子和一个氮原子，环A和环B共享一个螺环碳原子），其盐、N-氧化物或溶剂化物，或其前药物。由于化合物（I）及其盐、N-氧化物或溶剂化物或其前药物具有对MBR的亲和力，它们对于预防和/或治疗由压力引起的疾病是有用的。
• INHIBITORS OF SERINE PALMITOYLTRANSFERASE
  申请人：Hutchings Richard

  公开号：US20080287479A1

  公开（公告）日：2008-11-20

  This invention provides compounds of the formula: useful in the inhibition or modulation of serine palmitoyl transferase and their use in methods of treatment or amelioration of type 2 diabetes, type 1 diabetes, insulin resistance, the effects of obesity, metabolic syndrome (sometimes referred to as Syndrome X), impaired glucose tolerance, Cushing's disease, cardiovascular disease, prothrombotic conditions, myocardial infarction, hypertension, congestive heart failure, cardiomyopathy, atherosclerosis, dyslipidemia, sepsis, liver damage, retinal degenerative disorders, cachexia, emphysema, hepatitis C infections, HIV infections and inflammatory disorders and useful in methods for raising HDL plasma levels in a mammal. The compounds of this invention can also be used to prevent damage or loss of pancreatic islet beta cells (such as in the case of pancreatic beta cell apoptosis, including those related to insulin-dependent diabetes mellitus).

  这项发明提供了以下式的化合物： 其中，这些化合物可用于抑制或调节丝氨酰棕榈酰转移酶，并在治疗或改善2型糖尿病、1型糖尿病、胰岛素抵抗、肥胖症、代谢综合征（有时称为X综合征）、糖耐量受损、库欣综合征、心血管疾病、促凝状态、心肌梗死、高血压、充血性心力衰竭、心肌病、动脉粥样硬化、血脂异常、败血症、肝损伤、视网膜退行性疾病、消瘦、肺气肿、丙型肝炎感染、HIV感染和炎症性疾病的治疗方法中使用，且可用于提高哺乳动物的高密度脂蛋白血浆水平的方法。 此发明的化合物还可用于预防胰岛β细胞的损伤或丢失（例如，胰岛β细胞凋亡的情况，包括与胰岛素依赖性糖尿病相关的凋亡）。